Alivus Life Sciences Ltd

- No explicit mention of any current or planned fundraising through debt or equity in the call transcript. - Glenmark Life Sciences continues to remain a net debt-free company. - Strong cash flow generation (INR 98 crores in the recent quarter) and substantial cash & cash equivalents (INR 308 crores as of June 30, 2023) strengthen the balance sheet. - Capital expenditure planned is between INR 150 crores to INR 200 crores for the year, mainly funded internally. - No discussion or indication of equity fundraising or debt issuance for expansion or other purposes was stated during the call.

- Glenmark Life Sciences plans calibrated capex of INR 150-200 crores for FY 2023-24. - Capex for the recent quarter (Q1 FY24) was INR 35 crores. - Focus on accelerating brownfield expansions at Dahej and Ankleshwar to add capacity faster and cost-effectively compared to greenfield projects. - Greenfield project at Solapur is ongoing but delayed slightly. - Additional capacities are being added at Dahej, Ankleshwar, and Solapur. - The company aims to ensure adequate capacity to support growing demand and CDMO projects. - Capex is strategic to meet growing business needs and support mid-teens revenue growth guidance.

- Glenmark Life Sciences expects mid-teens growth in revenue for FY '24, supported by improved demand and favorable pricing environment. - The company anticipates strong growth momentum in coming quarters, driven by growth in regulated markets, CDMO business, and emerging markets. - CDMO business is on an upward trajectory, aiming to cross INR200 crores revenue this year, up from INR120 crores last year, with new projects expected to kick in Q3-Q4. - Over a 5-year horizon, CDMO revenue is expected to grow from approx. INR150 crores to about INR600 crores, increasing its contribution to 14-15% of total revenue. - New molecule launches are expected to play a significant role in overall growth, contributing up to 50% of total revenue incrementally over the next 5 years. - Capacity expansions and regulatory approvals are expected to support sustained volume increases. - Operating margins are expected to remain stable to slightly higher, depending on product mix and raw material pricing.

- Glenmark Life Sciences expects strong growth momentum to continue, with mid-teens revenue growth guidance for FY '24. - Margins are expected to remain stable to slightly higher, depending on product mix. - CDMO business is growing with revenue potentially crossing INR200 crores this year, contributing positively to margins. - New molecule launches are anticipated to contribute significantly, with an expected 50% revenue contribution over the next 5 years. - Operating leverage from new plant capacities at Dahej, Ankleshwar, and Solapur is expected as utilization improves. - R&D expenditure is maintained around 3% of sales, supporting pipeline growth and innovation. - The company has generated strong free cash flow, supporting a healthy balance sheet and potential dividends. - External demand recovery and better input cost environment boost profitability prospects. - However, cautious outlook is maintained due to raw material price fluctuations and uncertain macroeconomic factors.

- Glenmark Life Sciences has multiple projects in the CDMO pipeline, with two new projects having reached significant milestones and advanced stages of discussion. - There are "quite a few" other active discussions for potential CDMO projects, though exact numbers are not specified. - Management does not expect to have as many as 10-11 active CDMO projects by FY 2025 but anticipates a gradual increase over the next 2-3 years. - For FY 2024, CDMO business is expected to contribute around 8-9% of total revenue, aiming to cross INR 200 crores. - One new CDMO project is expected to start contributing significantly by Q4 FY 2024. - Existing three commercial CDMO projects are stable and expected to continue delivering at current levels. - The company remains cautiously optimistic due to regulatory and market uncertainties.